Organon & Co. (OGN)
NYSE: OGN · Real-Time Price · USD
16.04
-0.08 (-0.50%)
Nov 8, 2024, 4:00 PM EST - Market closed
Organon & Co. Revenue
Organon & Co. had revenue of $1.58B in the quarter ending September 30, 2024, with 4.15% growth. This brings the company's revenue in the last twelve months to $6.41B, up 4.21% year-over-year. In the year 2023, Organon & Co. had annual revenue of $6.26B with 1.44% growth.
Revenue (ttm)
$6.41B
Revenue Growth
+4.21%
P/S Ratio
0.64
Revenue / Employee
$640,900
Employees
10,000
Market Cap
4.13B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Option Care Health | 4.78B |
Acadia Healthcare Company | 3.12B |
ICU Medical | 2.30B |
Haemonetics | 1.36B |
Prestige Consumer Healthcare | 1.11B |
Axsome Therapeutics | 291.49M |
TG Therapeutics | 264.79M |
Rhythm Pharmaceuticals | 112.53M |
OGN News
- 9 days ago - Organon & Co. (OGN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Organon Reports Results for the Third Quarter Ended September 30, 2024 - Business Wire
- 12 days ago - Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% - Business Wire
- 19 days ago - Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4 - Benzinga
- 19 days ago - 5 Stocks to Buy for a Harris Presidency - Kiplinger
- 19 days ago - Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
- 4 weeks ago - Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024 - Business Wire
- 7 weeks ago - Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B - Benzinga